Direct and Natural Killer Cell-Mediated Antitumor Effects of Low-Dose Bortezomib in Hepatocellular Carcinoma

URN to cite this document:: urn:nbn:de:bvb:355-epub-589406
DOI to cite this document:: 10.5283/epub.58940

Armeanu-Ebinger, Sorin ; Krusch, Matthias ; Baltz, Katrin M. ; Weiss, Thomas S.

; Smirnow, Irina ; Steinle, Alexander

; Lauer, Ulrich M. ; Bitzer, Michael ; Salih, Helmut R.

License: Creative Commons Attribution Non-commercial No Derivatives 4.0
PDF - Published Version
(507kB)

Date of publication of this fulltext: 19 Aug 2024 13:06

Alternative links to fulltext:DOI Publisher

Details

Preview

Indexed in

Export bibliographical data

Abstract

Purpose: Hepatocellular carcinoma (HCC) displays particular resistance to conventional cytostatic agents. Alternative treatment strategies focus on novel substances exhibiting antineoplastic and/or immunomodulatory activity enhancing for example natural killer (NK) cell antitumor reactivity. However, tumor-associated ligands engaging activating NK cell receptors are largely unknown. Exceptions ...